Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 31, 2014
Pharmacy Choice - News - U.S. Pharmaceutical Industry - October 31, 2014

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/31/14 - Immunomedics Provides Update On Phase 2 Study Of Isactuzumab Govitecan; Hemispherx Reports New Evidence of Ampligen(R)
{nfg} Immunomedics, Inc., announced isactuzumab govitecan, the Company's proprietary solid-tumor antibody-drug conjugate, continues to produce encouraging results in a Phase 2 clinical trial in heavily-pretreated patients with diverse, metastatic solid cancers. David M. Goldenberg, Chairman, Chief Scientific Officer, and Chief Medical Officer, at t
10/31/14 - U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo's Once-Daily SAVAYSA? (edoxaban) for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation
"We are confident that the outcomes and robustness of the ENGAGE AF-TIMI 48 study fully support the approval in the U.S. of the 60 mg dosing regimen of SAVAYSA for patients with NVAF, with a dose reduction to 30 mg in selected patients," said Glenn Gormley, MD, PhD, Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Company, Limited an
10/30/14 - "Pharmaceutical Composition for Peroral Administration of 3,3'-Diindolylmethane" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Women's Health Weekly A patent application by the inventors KISELEV, Vsevolod Ivanovich; VASSILIEVA, Irina Gennadievna, filed on June 20, 2014, was made available online on October 16, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has
10/30/14 - AB Science: publication of preclinical data on the neuroprotective effect of masitinib
AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announces the publication of preclinical study results with masitinib in ischemic stroke. Entitled,' Neuroprotective effect of masitinib in rats with postischemic stroke' this article and its accompanying...
10/30/14 - ABIVAX Strengthens Executive Management Team With Senior Appointments
Daniel Kenny appointed Chief Commercial Officer& VP of Business Development. ABIVAX, the Paris- based clinical stage biopharmaceutical company specialised in the development and commercialisation of therapeutic vaccines and anti-viral compounds, today announced the appointments of Karl Birthistle, M.D., and Daniel Kenny to its Executive Management.
10/30/14 - Advaxis's ADXS-cHER2 Immunotherapy Demonstrates T-Cell Immune Response in Data Analysis From Canine Osteosarcoma Study
Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced that a data analysis of its ongoing Phase 1 clinical study of ADXS-cHER2 in canine osteosarcoma indicates that the immunotherapy breaks peripheral tolerance to HER2/Neu and induces HER2-specific T cell responses in dogs. David J. Mauro, M.D.,
10/30/14 - Aegerion Pharmaceuticals Announces Third-Quarter 2014 Financial Results
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced its financial results and business highlights for the third-quarter of 2014.. Aegerion recorded $43.7 million in net product sales of JUXTAPID capsules in
10/30/14 - Alnylam to Webcast Presentation at the Nomura Biotechnology Conference
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that management will present a company overview at the Nomura Biotechnology Conference on Thursday, November 6, 2014 at 9:00 a.m. ET at the Mandarin Oriental in Boston. About Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company developing novel therapeutic
10/30/14 - AMAG Pharmaceuticals Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2014
"In addition to driving growth of Feraheme, we also are executing on our long-term strategic plan to expand and diversify our product portfolio through our recently announced agreement to acquire Lumara Health Inc. We believe the Lumara Health business will facilitate future product acquisitions in an attractive new therapeutic area and is an excel
10/30/14 - Anacor Pharmaceuticals Announces Third Quarter 2014 Financial Results Conference Call and Webcast
Anacor Pharmaceuticals, Inc. will release its financial results for the third quarter ended September 30, 2014, on Thursday, November 6, 2014 at approximately 4:00 p.m. ET/ 1:00 p.m. PT. Anacor s first approved drug, KERYDIN TM topical solution, 5%, is an oxaborole antifungal approved by the U.S. Food and Drug Administration in July 2014 for the
10/30/14 - AnaMar AB Reports Top-Line Results from Exploratory Phase 2a Study of AMAP102 and Provides Corporate Update
In the reported exploratory Phase 2 a trial, AMAP102, a 5- HT 2 B receptor antagonist, was well tolerated with no reported serious adverse events, but fell short of demonstrating a statistically significant reduction in pain over a 28- day period compared to placebo, as measured using the Western Ontario and McMaster Universities Arthritis Index pa
10/30/14 - Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines
-Atlantic Canadians will save an estimated $560- million through an unprecedented three-year agreement reached between Canada's provinces and territories and the generic pharmaceutical industry, Jim Keon, President of the Canadian Generic Pharmaceutical Association, said today. "This national framework provides enormous additional savings to the..
10/30/14 - Auspex Pharmaceuticals Initiates Second Pivotal Clinical Trial for SD-809 in Tardive Dyskinesia
Auspex Pharmaceuticals, Inc., a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced the enrollment of the first patient in a multi-center Phase 3 clinical trial of its investigational drug SD-809 for the treatment of people with tardive dyskinesia.
10/30/14 - Avalanche Biotechnologies to Participate in Nomura's Biotechnology Conference
Avalanche Biotechnologies, Inc., a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that Linda C. Bain, Chief Financial Officer, will participate in the "From Successful IPOs to Clinical Success: A Focus on
10/30/14 - B. Braun to Promote Drug Development Products at 2014 AAPS Annual Meeting and Exposition
B. Braun's OEM Division will attend the 2014 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, November 2-6, at the San Diego Convention Center in San Diego, Calif.. B. Braun's OEM Division will promote products and packaging that pharmaceutical and biotech companies can use throughout their product life cycles from d
10/30/14 - Celator(R) Pharmaceuticals to Present on Liposome Delivery Systems at 2014 American Association of Pharmaceutical Scientists Annual Meeting
Celator Pharmaceuticals, Inc., a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Dr. Lawrence Mayer, President, Founder and Chief Scientific Officer of Celator, will present at the 2014 American Association of Pharmaceutical Scien
10/30/14 - CHPA -Biopharmaceutical Research and Manufacturing Sector Oppose Drug Take Back Ordinance
The following statement can be attributed to BayBio, the Biotechnology Industry Organization, the Pharmaceutical Research and Manufacturers of America, the Generic Pharmaceutical Association and the Consumer Healthcare Products Association:. However, there is no rationale for mandating new, costly and redundant disposal options when both the Food a
10/30/14 - Chugai licenses ISPRI/OptiMatrix platform from EpiVax for de-risking biologics
Chugai Pharmaceutical Co., Ltd., signed an agreement with Rhode Island- based biotechnology company, EpiVax, Inc., to incorporate EpiVax's ISPRI immunogenicity screening and deimmunization technology into Chugai's drug development toolbox. Chugai is widely regarded as one of the most cutting edge biopharmaceutical companies in Japan.
10/30/14 - Conn. biotech company in process of developing Ebola vaccine [EMBIN (Emerging Markets Business Information News]
Protein Sciences, located in Meriden, is a month away from having vaccine material ready to be shipped to the National Institutes of Health, with human clinical testing in sight by the end of the year, said Manon Cox, president and CEO of the company. That protein has been shown to trigger antibodies ? agents of the body's defense system
10/30/14 - CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium
The presentation, titled, "Drug Conjugates Bind Covalently to Albumin: A New Approach," will be given by Sant P. Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center and principal investigator of the Company's ongoing global, pivotal Phase 3 aldoxorubicin clinical trial in second-line soft tissue sarcoma, at the 2014 Chemotherapy Found
10/30/14 - Discovery Labs Announces Organizational Change and Enhanced Expertise in Neonatology
Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced organizational changes to the development leadership team and a special advisory appointment to augment the company's expertise in neonatology and aerosolized drug delivery. Dr. Simonson joined...
10/30/14 - EBS Technologies Opens Its Second Clinic, Reports Continuing Efficacy Using Noninvasive Electrical Brain Stimulation System Designed to Expand Visual Field of Patients with Impaired Vision
EBS Technologies announced today that it has opened a second clinic in Germany to treat patients who have impaired vision using its patented noninvasive electrical brain stimulation system NEXT WAVE? to expand the patients visual field. NEXT WAVE? is approved for sale in Europe. In fact, three out of five persons disabled from impaired
10/30/14 - Edwards Highlights Benefits of Dry Vacuum Solutions for Pharmaceutical Market
Edwards is highlighting the benefits that their dry vacuum pumps can bring to the pharmaceutical market at Pharma Expo, Chicago, Illinois, 2-5 November. Industry expert from Edwards, Jeff Luby, will be presenting a paper at the conference on Monday November 3 rd at 1 pm, Intelligent Vacuum Pumping Solutions for the Pharmaceutical Market. Visi
10/30/14 - FDA Approves Protein Sciences Flu Vaccine For Older Americans [The Hartford Courant]
Oct. 30 The Food and Drug Administration has extended its approval the flu vaccine made by Meriden's Protein Sciences to adults 50 years old and above. The vaccine, Flublok, acquired its first stamp of approval from federal regulators in January 2013, but only for those aged 18 to 49. Making the drug available to older people is important for pub
10/30/14 - GeoVax CEO Interviewed on the Fox Business Network
ATLANTA, GA/ ACCESSWIRE/ October 30, 2014/ Robert T. McNally, PhD, President& CEO of GeoVax Labs, Inc., a biotechnology company developing innovative human vaccines using its novel DNA/MVA platform technology, was recently interviewed on the Fox Business Network's The Willis Report and on MONEY with Melissa Francis, discussing GeoVax's Ebola vaccin
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


The Diversion of Controlled Substances and the Law
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement